In New Delhi: The CERVAVAC cervical cancer vaccine, produced in India by The Serum Institute of India, will go on sale this month for Rs 2,000 per vial of two doses, according to government sources on Thursday. On January 24, the first domestic human papillomavirus (HPV) vaccination was introduced by Union Home Minister Amit Shah in the presence of the CEO and Director of Government and Regulatory Affairs of the Serum Institute of India (SII), Adar Poonawalla.
Singh has reportedly written a letter to the Union Health Ministry stating that the cost of its HPV vaccine for the private market will be Rs 2,000 per vial of two doses, which is significantly less than the cost of other HPV vaccinations already on the market. The Serum Institute is prepared to launch CERVAVAC on the private market starting this month after hospitals, physicians, and associations approached the company in search of its HPV vaccine.
According to information obtained, Singh also stated in his letter that SII will offer their HPV vaccination at a very low cost whenever the Health Ministry purchases it. For HPV vaccines right now, the nation is totally dependent on foreign producers. Only one HPV vaccination is now offered in the private market in a single-dose pre-filled syringe form, and it costs Rs 10,850. That vaccine is Gardasil, made by American multinational Merck. The national immunization program for girls aged 9 to 14 will include the HPV vaccine against cervical cancer in June, and the Union Health Ministry expects to launch a global tender for it in April.
India is home to around 16% of all women worldwide, yet it has a quarter of all cervical cancer cases and close to a third of all cervical cancer fatalities. According to officials, Indian women have a 1.6% lifetime cumulative risk of having cervical cancer and a 1% lifetime cumulative risk of dying from the disease. According to some recent estimates, in India each year, 35,000 women pass away from cervical cancer and close to 80,000 develop the disease.
IR Research Publication is Publisher, Editorial, and Profile Building Service Provider. It Covers the Publication of Multiple Reputed Journals in the field of Biological, Medical, Pharmaceutical, and Life Sciences. IR Research Publication provides news on CDSCO decisions and FDA decisions, pharmaceutical industries, generic drugs, patents, and other pharma news.
For more details visit the link- https://irrespub.com/